Sixth Street Specialty Lending, Inc. Prices Public Offering of $300.0 million 6.950% Unsecured Notes due 2028
NEW YORK–(BUSINESS WIRE)–Sixth Street Specialty Lending, Inc. (NYSE:TSLX) (“TSLX” or the “Company”) announced today that…
NEW YORK–(BUSINESS WIRE)–Sixth Street Specialty Lending, Inc. (NYSE:TSLX) (“TSLX” or the “Company”) announced today that…
HONG KONG, Aug 8, 2023 – (ACN Newswire) – In February 2023, ChatGPT, OpenAI’s text-generating…
RIYADH, Aug 8, 2023 – (ACN Newswire) – The Saudi Film Commission is expected to…
LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical…
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR)…
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS-…
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP)…
First patients dosed in the BDC-1001 Phase 2 program BDC-1001 Phase 1 data presented at…
Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of…
QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with…
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader…
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic…
– Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of…
Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel…
-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment…
Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European…
Acquisition is Expected to Position Tilray as the 5th1 Largest Craft Beer Brewer in the…
Submitted proposed pivotal trial protocol for Anaphylm™ (epinephrine) Sublingual Film to the FDA Submitted an…
SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a…
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer…